Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies

[1] Locatelli F(2017)Targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients Am J Nephrol 45 187-199

[2] Fishbane S(2012)Mechanisms of anemia in CKD J Am Soc Nephrol 23 1631-1634

[3] Block GA(2003)Anemia as a risk factor for cardiovascular disease Kidney Int Suppl 87 S32-S39

[4] Macdougall IC(2019)In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study BMC Nephrol 20 359-330

[5] Babitt JL(2007)Erythropoiesis-stimulating agent hyporesponsiveness Nephrology (Carlton) 12 321-590

[6] Lin HY(1998)The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 584-2032

[7] Pereira AA(2009)A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 2019-2098

[8] Sarnak MJ(2006)Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 2085-319

[9] Ingrasciotta Y(2013)Peginesatide in patients with anemia undergoing hemodialysis N Engl J Med 368 307-353

[10] Lacava V(2012)The new FDA labeling for ESA–implications for patients and providers Clin J Am Soc Nephrol 7 348-1083

[1] Locatelli F(2017)Targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients Am J Nephrol 45 187-199

[2] Fishbane S(2012)Mechanisms of anemia in CKD J Am Soc Nephrol 23 1631-1634

[3] Block GA(2003)Anemia as a risk factor for cardiovascular disease Kidney Int Suppl 87 S32-S39

[4] Macdougall IC(2019)In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study BMC Nephrol 20 359-330

[5] Babitt JL(2007)Erythropoiesis-stimulating agent hyporesponsiveness Nephrology (Carlton) 12 321-590

[6] Lin HY(1998)The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 584-2032

[7] Pereira AA(2009)A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 2019-2098

[8] Sarnak MJ(2006)Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 2085-319

[9] Ingrasciotta Y(2013)Peginesatide in patients with anemia undergoing hemodialysis N Engl J Med 368 307-353

[10] Lacava V(2012)The new FDA labeling for ESA–implications for patients and providers Clin J Am Soc Nephrol 7 348-1083